» Articles » PMID: 15246826

Impact of the Selective Estrogen Receptor Modulator, Tamoxifen, on Neuronal Outgrowth and Survival Following Toxic Insults Associated with Aging and Alzheimer's Disease

Overview
Journal Exp Neurol
Specialty Neurology
Date 2004 Jul 13
PMID 15246826
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the estrogen agonist/antagonist properties of the selective estrogen receptor modulators (SERMs), tamoxifen (TMX) and 4-hydroxy-tamoxifen (OHT), using an in vitro neuron model system to determine the impact of the neuroprotective and neurotrophic properties of these SERMs. Low concentrations of TMX or OHT were without effect on a marker of neuronal viability, basal release of lactate dehydrogenase (LDH), whereas high concentrations of both SERMs (2500 ng/ml) induced a significant increase in LDH, indicating the potential toxicity of both SERMs at high concentrations. Subsequent experiments revealed that subtoxic concentrations of both TMX and OHT induced significant neuroprotection against beta-amyloid(25-35)-induced toxicity; 15-20% and 10-15% (P < 0.05), respectively and also against glutamate-induced toxicity; 25-30% and 20-40% (P < 0.05 and P < 0.01), respectively. Additional in vitro experiments included analysis of neuron survival to determine whether the SERM, OHT, acted competitively or synergistically with the endogenous estrogen, 17 beta-estradiol (E2). These revealed that neuron survival following exposure to the neurotoxins beta-amyloid and excitotoxic glutamate was significantly increased in cultures treated with OHT (50 ng/ml) (10%, P < 0.01) and that the magnitude of survival was equivalent to E2 (10 ng/ml). The combined presence of OHT and E2 significantly protected against both beta-amyloid(25-35) and excitotoxic glutamate-induced neuron death (10%, P < 0.01) but was not significantly different from either OHT or E2 alone. To assess neurotrophic effects of these same SERMs, cultured neurons from brain regions involved in memory function and Alzheimer's disease were evaluated by morphological analysis of individual neurons. Results of these analyses demonstrated that TMX treatment did not significantly increase the process outgrowth or morphological complexity of cortical, hippocampal, or basal forebrain neurons. Similar analyses showed that OHT also failed to significantly increase the neuronal outgrowth of either cortical or hippocampal neurons. Results of these studies predict that TMX and OHT could exert a neuroprotective function but would not promote estrogen-dependent memory function.

Citing Articles

Breast cancer therapies reduce risk of Alzheimer's disease and promote estrogenic pathways and action in brain.

Branigan G, Torrandell-Haro G, Chen S, Shang Y, Perez-Miller S, Mao Z iScience. 2023; 26(11):108316.

PMID: 38026173 PMC: 10663748. DOI: 10.1016/j.isci.2023.108316.


Estrogen signaling via estrogen receptor alpha and its implications for neurodegeneration associated with Alzheimer's disease in aging women.

Tecalco-Cruz A, Lopez-Canovas L, Azuara-Liceaga E Metab Brain Dis. 2023; 38(3):783-793.

PMID: 36640216 DOI: 10.1007/s11011-023-01161-2.


Targeting Estrogen Signaling in the Radiation-induced Neurodegeneration: A Possible Role of Phytoestrogens.

Mitra S, Dash R, Sohel M, Chowdhury A, Munni Y, Ali M Curr Neuropharmacol. 2022; 21(2):353-379.

PMID: 35272592 PMC: 10190149. DOI: 10.2174/1570159X20666220310115004.


Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo-PrP binding and downstream pathways.

Grayson J, Baumgartner M, Souza C, Dawes S, Ghafir El Idrissi I, Louth J Chem Sci. 2021; 12(10):3768-3785.

PMID: 34163650 PMC: 8179515. DOI: 10.1039/d0sc04769d.


Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.

Branigan G, Soto M, Neumayer L, Rodgers K, Brinton R JAMA Netw Open. 2020; 3(3):e201541.

PMID: 32207833 PMC: 7093781. DOI: 10.1001/jamanetworkopen.2020.1541.